Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

Coronavirus belongs to the family of Coronaviridae, comprising single-stranded, positive-
sense RNA genome (+ ssRNA) of around 26 to 32 kilobases, and has been known to cause …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

NANOBODY®(a registered trademark of Ablynx NV) molecules (Nbs), also referred to as
single domain-based VHHs, are antibody fragments derived from heavy-chain only IgG …

INTRODUCTION The global scale and rapid spread of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pose unprecedented challenges to society, health care …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells
via an interaction between its Spike protein and the host cell receptor angiotensin …

Summary SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern
regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …